NCT04844749Phase 3Terminated

Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent

Study sponsor: Veru Inc. · VERU

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2023-05-04Actual
Enrollment · participants105Actual
Source updated2024-02-05Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview